HARROW, INC. HROW

Latest FY: 2025 Healthcare Drug Manufacturers - Specialty & Generic
Market Price $36.59
Market Cap $1.36B
P/E Ratio N/A
Quick Peer Compare (Healthcare):
Revenue (FY 2025) ↑36.4% YoY
$272.30M
3-Yr CAGR: 45.4%
Net Income ↑70.6% YoY
-$5.14M
Net Margin: -1.9%
Free Cash Flow ↑280.6% YoY
$42.98M
FCF Yield: 3.15%
EPS (Diluted) ↑71.4% YoY
$-0.14
Basic: $-0.14
Return on Equity Efficiency
-9.8%
ROA: -1.3%

📊 Multi-Year Historical Performance & Trends

Financial Performance History Revenue, Net Income & Free Cash Flow
Margins Trend (%) Gross, Operating & Net Margins
Balance Sheet Strength Cash, Debt & Equity
Cash Flow Generation Operating Cash Flow vs CapEx vs FCF

📈 Year-over-Year (YoY) Growth History (HROW)

All monetary values in millions ($M)
Fiscal Year Revenue Revenue YoY Gross Profit Net Income Net Inc YoY Diluted EPS EPS YoY Div / Sh Div Yield Op. Cash Flow Free Cash Flow FCF YoY
FY 2016 $19.9M $10.1M $-19.1M 0.00% $-11.2M $-18.1M
FY 2017 $26.8M +34.3% $13.3M $-12.0M +37.2% $-0.60 0.00% $-8.8M $-9.6M +47.1%
FY 2018 $41.4M +54.5% $24.9M $14.6M +222.0% $0.61 +201.7% 0.00% $0.7M $-1.1M +88.7%
FY 2019 $51.2M +23.7% $34.4M $0.2M -98.9% $0.01 -98.4% 0.00% $0.9M $-0.5M +52.1%
FY 2020 $48.9M -4.5% $34.4M $-3.4M -2,098.2% $-0.13 -1,400.0% 0.00% $-1.1M $-2.0M -278.8%
FY 2021 $72.5M +48.3% $54.3M $-18.0M -436.4% $-0.69 -430.8% 0.00% $5.1M $3.3M +268.0%
FY 2022 $88.6M +22.2% $63.2M $-14.1M +21.8% $-0.51 +26.1% 0.00% $1.7M $-0.9M -127.1%
FY 2023 $130.2M +47.0% $90.6M $-24.4M -73.3% $-0.75 -47.1% 0.00% $3.8M $2.4M +366.8%
FY 2024 $199.6M +53.3% $150.4M $-17.5M +28.4% $-0.49 +34.7% 0.00% $-22.2M $-23.8M -1,099.9%
FY 2025 $272.3M +36.4% $204.4M $-5.1M +70.6% $-0.14 +71.4% 0.00% $43.9M $43.0M +280.6%
$

Valuation

Market Price $36.59
Market Cap $1.36B
Enterprise Value $1.54B
P/E Ratio N/A
P/B Ratio 26.01
FCF Yield 3.15%
Dividend Yield N/A
Shares Outstanding 37,275,100
%

Profitability & Margins

Gross Margin 75.05%
Operating Margin 11.21%
Net Margin -1.89%
Return on Equity (ROE) -9.80%
Return on Assets (ROA) -1.29%
Asset Turnover 0.68x
Revenue 3-Yr CAGR 45.39%
🛡️

Financial Health & Liquidity

Current Ratio 2.20
Cash Ratio 0.76
Debt / Equity 4.767
Debt / Assets 0.626
Cash & Equivalents $72.93M
Total Debt $250.00M
Book Value / Share $1.41
💧

Cash Flow Efficiency

Operating Cash Flow $43.86M
Capital Expenditures (CapEx) $887.00K
Free Cash Flow $42.98M
OCF / Revenue 16.11%
FCF / Revenue 15.78%
FCF 3-Yr CAGR N/A
🏷️

Per Share Metrics

EPS (Diluted) $-0.14
EPS (Basic) $-0.14
Dividends / Share N/A
Book Value / Share $1.41
EPS YoY Growth 71.43%
🏛️

Balance Sheet (FY 2025)

Total Assets $399.48M
Total Liabilities $347.39M
Stockholders' Equity $52.45M
Current Assets $211.75M
Current Liabilities $96.30M